Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, Barbarot S, Szepietowski JC, Conrad C, Pink AE, Weisshaar E, Misery L, Metz M, Laquer VT, Sivamani RK, Yosipovitch G, Thaçi D, Skov L, Chen X, Noda A, Jabbar-Lopez ZK, Piketty C, Ständer S

Open source

DOI: 10.1111/jdv.70266
Published: 2026 Jul
Container: Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jdv.70266,
  title = {Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.},
  author = {Legat FJ and Kwatra SG and Reich A and Boulinguez S and Tsianakas A and Sauder M and Barbarot S and Szepietowski JC and Conrad C and Pink AE and Weisshaar E and Misery L and Metz M and Laquer VT and Sivamani RK and Yosipovitch G and Thaçi D and Skov L and Chen X and Noda A and Jabbar-Lopez ZK and Piketty C and Ständer S},
  year = {2026},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  doi = {10.1111/jdv.70266},
  url = {https://doi.org/10.1111/jdv.70266}
}

RIS

TY  - JOUR
TI  - Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.
AU  - Legat FJ
AU  - Kwatra SG
AU  - Reich A
AU  - Boulinguez S
AU  - Tsianakas A
AU  - Sauder M
AU  - Barbarot S
AU  - Szepietowski JC
AU  - Conrad C
AU  - Pink AE
AU  - Weisshaar E
AU  - Misery L
AU  - Metz M
AU  - Laquer VT
AU  - Sivamani RK
AU  - Yosipovitch G
AU  - Thaçi D
AU  - Skov L
AU  - Chen X
AU  - Noda A
AU  - Jabbar-Lopez ZK
AU  - Piketty C
AU  - Ständer S
PY  - 2026
JO  - Journal of the European Academy of Dermatology and Venereology : JEADV
DO  - 10.1111/jdv.70266
UR  - https://doi.org/10.1111/jdv.70266
ER  -

APA

FJ, L., SG, K., A, R., S, B., A, T., M, S., S, B., JC, S., C, C., AE, P., E, W., L, M., M, M., VT, L., RK, S., G, Y., D, T., L, S., X, C., A, N., ZK, J., C, P., & S, S. (2026). Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70266

Source records

pubmed · retrieved 2026-09-26T03:13:55.070Z